<DOC>
	<DOCNO>NCT02504827</DOCNO>
	<brief_summary>The purpose research study characterize pharmacokinetics intravenous ceftazidime/avibactam patient Cystic Fibrosis .</brief_summary>
	<brief_title>Steady-state Pharmacokinetics Ceftazidime/Avibactam Cystic Fibrosis</brief_title>
	<detailed_description>Cystic fibrosis genetic disorder characterize chronic cycle airway infection , obstruction , inflammation lead progressive loss lung function eventual respiratory failure . The principal pathogen Pseudomonas aeruginosa present airways 70 % adult patient CF . Of particular concern increase resistance observe exist agent . While ceftazidime mainstay treatment many year , efficacy limit reduced susceptibility . Ceftazidime/avibactam offer potential advancement management infection involve P. aeruginosa CF due excellent activity , penetration pulmonary secretion , reduce potential development resistance .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<criteria>Diagnosis CF base positive sweat chloride know CF mutation Age &gt; 17 year Able spontaneously expectorate sputum Any clinically significant laboratory abnormality Presence ongoing acute pulmonary exacerbation Pregnancy Serious past allergy betalactam antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>ceftazidime/avibactam</keyword>
</DOC>